Navigation Links
Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
Date:10/31/2011

HOUSTON, Oct. 31, 2011 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced that the U.S. Food and Drug Administration ("FDA") approved a significant expansion of options for Magnetic Resonance Imaging ("MRI") use by patients who have the VNS Therapy System.

The expansion includes:

  • New: All cylindrical MRI scanners with magnetic field strengths of 3.0 and 1.5 Tesla; Previous: GE Signa 1.5 Tesla scanner only
  • New: Imaging of head and extremities, including knees, using transmit/receive coils; Previous: head imaging only using transmit/receive coils

"This approval will enable VNS Therapy System patients to obtain access to the faster, higher resolution imaging available with 3.0 Tesla MRI scanners," commented Dan Moore, Cyberonics' President & Chief Executive Officer.  "Our VNS technology, coupled with this approval, provides physicians with expanded imaging options for patients with epilepsy.

"We are pleased that the FDA has been responsive to patient needs and granted this approval."

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers electrical pulsed signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

A full description of the revised MRI labeling will be available at www.cyberonics.com, along with additional information on Cyberonics and th
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cyberonics Announces Resignation of James A. Reinstein, Senior Vice President & Chief Commercial Officer
2. Cyberonics Announces Investment in ImThera Medical
3. Cyberonics to Participate in 2011 UBS Global Life Sciences Conference
4. Cyberonics Reports Fiscal 2012 First Quarter Results
5. Cyberonics to Report Fiscal Year 2012 First Quarter Results and Host Conference Call on August 25, 2011
6. Cyberonics Reports Record Fiscal 2011 Results and Provides Fiscal 2012 Guidance
7. Cyberonics to Participate in 2011 Jefferies Global Healthcare Conference
8. Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance
9. Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011
10. Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference
11. Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... 28, 2011 Tengion, Inc. (Nasdaq: TNGN ) ... to its Board of Directors. Mr. Flora brings to Tengion ... wound healing and surgical device businesses.  He most recently served ... Tengion also announced today that Gary Kurtzman, ...
... SOUTH SAN FRANCISCO, Calif., Sept. 28, 2011 Onyx ... that it has completed the New Drug Application (NDA) ... under the accelerated approval process for carfilzomib, a next ... with relapsed and refractory multiple myeloma. In addition, Onyx ...
Cached Medicine Technology:Tengion Appoints Scott Flora to Board of Directors 2Tengion Appoints Scott Flora to Board of Directors 3Tengion Appoints Scott Flora to Board of Directors 4Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 3Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 4
(Date:8/21/2014)... 2014Popular fiction that normalizes and glamorizes violence against women, ... associated with a greater risk of potentially harmful health ... study are presented in the article " Fiction or ... Adolescent and Young Adult Females ," published in ... Mary Ann Liebert, Inc., publishers . The article ...
(Date:8/21/2014)... Individuals with schizophrenia often have trouble engaging in ... new study from San Francisco State University suggests the ... of effort required to complete tasks. , The research, ... Journal of Abnormal Psychology , can assist health ... and help those patients function normally by breaking up ...
(Date:8/21/2014)... Entries are now open for the ... national awards program totally dedicated to recognizing excellence in ... leadership. The entry deadline is Oct. 17. , The ... the first and only national magazine entirely devoted to ... “We launched the HREI Insights Awards program last year ...
(Date:8/21/2014)... 2014 Recently it came to the ... located in Massachusetts has made public claims on August ... patient verification system in the Massachusetts cannabis industry. While ... our growing and compassionate industry we must set the ... are inaccurate. , MarijuanaDoctors.com has actually been providing ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... respiratory syncytial virus (RSV), a leading cause of pneumonia in ... in being able to treat human RSV infections -- the ... to influenza virus," said study author Dr. John DeVincenzo, a ... Medicine in Memphis. "There is no current treatment ...
Breaking Medicine News(10 mins):Health News:Women's health and Fifty Shades: Increased risks for young adult readers? 2Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3
... who undergo heart surgery fare better if they receive ... ,Investigators say that children who received reconstituted ... cells and plasma -- tended to accumulate less fluid, ... the study, researchers compared results for 200 infants who ...
... the brain using the CyberKnife frameless radiosurgery can successfully ... CyberKnife is a non-invasive robotic radiosurgical device that can ... uses a robotic arm, controlled by a computer, that ... tumor site. ,During the study researchers examined ...
... are obese when they are diagnosed with early-stage breast cancer ... women of normal weight.// ,Studies in the past have ... development, and has also shown to have contradictory results about ... latest study researchers say, they have demonstrated a significant association ...
... is an often disabling condition that affects primarily women. ... cannot be overcome with rest and often worsens with ... and there are no diagnostic tests or cures. A ... are at increased risk for developing chronic fatigue later ...
... in restoring sudden onset hearing loss. Researchers say sudden hearing ... of the sudden hearing loss can be identified in only ... includes viral and bacterial diseases, and metabolic, neurologic and immunologic ... which case there is no known cause. ,Previous research ...
... that affects more than 80 percent of teenagers and up ... cited // as a source of acne, these claims have ... this study. Each participant had at least one academic examination ... sources of stress for students. Stress levels were recorded using ...
Cached Medicine News:
...
...
Bimanual I&A Cannulas. Curved 45 with a .51mm open-end irrigation port. Facilitates removal of cortical debris between 10-2 o'clock. .80mm x 17.0mm...
...
Medicine Products: